<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643201</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-056</org_study_id>
    <secondary_id>EUDRACT: 2007-007867-25</secondary_id>
    <nct_id>NCT00643201</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism</brief_title>
  <official_title>A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of an investigational blood thinner,
      apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients with deep
      vein thrombosis (DVT) or pulmonary embolism (PE)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)</time_frame>
    <description>VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death</measure>
    <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death</measure>
    <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding</measure>
    <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding</measure>
    <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period</measure>
    <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period</measure>
    <time_frame>Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All-Cause Death During the Intended Treatment Period</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants</measure>
    <time_frame>First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued</time_frame>
    <description>Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: &lt; 0.75*LLN, &gt; 1.25*ULN; Hemoglobin: &lt;= 11.5 g/dL (males), &lt;= 9.5 g/dL (females); Hematocrit: &lt;= 37% (males), &lt;= 32% (females); Erythrocytes: &lt;0.75*10^6 c/µL*PreRx; Platelet count: &lt; 75*10^9 c/L, &gt; 700*10^9 c/L; ANC: &lt; 1.00*10^3 c/µL; Abs eosinophils: &gt; 0.750*10^3 c/µL; Abs Basophils: &gt; 400/MM^3; Abs Monocytes&gt; 2000/MM^3; Abs Lymphocytes: &lt; 0.750*10*3 c/ µL, &gt; 7.5*10^3 c/ µL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Bicarbonate milliequivalents/Liter (mEq/L) Low/High: &lt; 0.75*LLN or &gt; 1.25*ULN, or if pre-dose &lt; LLN then use &lt; 0.75*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.25*pre-dose or &lt; LLN; Serum Calcium mg/dL Low/High: &lt; 0.8*LLN or &gt; 1.2*ULN, or if pre-dose &lt; LLN then use &lt; 0.75*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.25*pre-dose or &lt; LLN; Serum Chloride mEq/L: &lt; 0.9*LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use &lt; 0.9*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.1*pre-dose or &lt; LLN; Serum Potassium mEq/L: &lt; 0.9*LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use &lt; 0.9*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.1*pre-dose or &lt; LLN; Serum Sodium mEq/L: &lt; 0.95*LLN or &gt; 1.05*ULN, or if pre-dose &lt; LLN then use &lt; 0.95*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.05*pre-dose or &lt; LLN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: &gt; 1.5*ULN; Creatinine mg/dL: &gt; 1.5*ULN; Alanine aminotransferase (ALT) U/L: &gt; 3*ULN; Aspartate aminotransferase (AST) U/L: &gt; 3*ULN; Alkaline phosphatase U/L: &gt; 2*ULN; Bilirubin Direct mg/dL: &gt; 1.5*ULN; Bilirubin Total mg/dL: &gt; 2*ULN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>Creatine kinase High: &gt;5*ULN Units/Liter (U/L); Total Protein High/Low: &lt; 0.9 *LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use 0.9* pre-dose or &gt; ULN if pre-dose &gt; ULN then use 1.1 *pre-dose or &lt;LLN; Uric acid High: &gt; 1.5* ULN, or if pre-dose &gt; ULN then use &gt; 2 *pre-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests</measure>
    <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
    <description>All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5614</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin + Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until international normalized ratio (INR) ≥2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>BMS-565793</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for apixaban</intervention_name>
    <description>tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for enoxaparin</intervention_name>
    <description>solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.</description>
    <arm_group_label>Enoxaparin + Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for warfarin</intervention_name>
    <description>tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
    <arm_group_label>Enoxaparin + Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <description>tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months</description>
    <arm_group_label>Enoxaparin + Warfarin</arm_group_label>
    <other_name>BMS-562247</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥ 18 years of age

          -  Clinical diagnosis of DVT or PE

        Exclusion Criteria:

          -  Contraindications for enoxaparin or warfarin

          -  Active bleeding or high risk for serious bleeding

          -  Short life expectancy

          -  Uncontrolled high blood pressure

          -  Significantly impaired kidney or liver function
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics, Llc</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Smith Lung Center</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Arkansas For Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaver Medical Group</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of California San Francisco-Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chest Medicine &amp; Critical Care Medical Gr. Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor Ucla Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New West Physicians</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drogue Medical, Llc</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept Of Internal Med, Sect Of Pulmonary &amp; Critical Care Med</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Pines Va Healthcare Systems</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel G. Lorch, Jr, Md, Cpi</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Alliance, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>River City Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasadena Center For Medical Research</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office Of Michele S. Maholtz Md</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Pulmonary Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Institute For Medical Research, Inc</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham Hospitalists</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gateway Cardiology. P.C</name>
      <address>
        <city>Jerseyville</city>
        <state>Illinois</state>
        <zip>62052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Suburban Medical Center</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Of Indiana Psc</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Vascular Medicine And Surgery</name>
      <address>
        <city>Windsor Heights</city>
        <state>Iowa</state>
        <zip>50324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Lung Clinic</name>
      <address>
        <city>Hazard</city>
        <state>Kentucky</state>
        <zip>41701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Of Kentucky Dept. Of Surgery</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Integrity, Llc</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pen Bay Medical Center</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Research Health Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mississippi Medical Research, Llc</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Missouri-Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School Of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John'S Mercy Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercury Street Medical Group, Pllc</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic, Llp</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medical Associates Of Grand Island, P.C</name>
      <address>
        <city>Grand Island</city>
        <state>Nebraska</state>
        <zip>68803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Critical Care Services, Pc</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaleida Health System</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richmond University Medical Center</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rex Healthcare</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare/Research</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Of America, Inc.</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Health System Clinic</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huron Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington Davis Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holston Medical Group</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kore Cv Research</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primecare Medical Group</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers Of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lake Washington Vascular, Pllc</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Research Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ciudad Autonoma De Buenos Aire</city>
        <state>Buenos Aires</state>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000CVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Windsor</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6001</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Belo Horizonte - Mg</city>
        <state>Minas Gerais</state>
        <zip>30150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80810</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>81520</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio Janeiro</city>
        <state>Rio De Janeiro</state>
        <zip>22280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Port Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liberdade</city>
        <state>Sao Paulo</state>
        <zip>01509</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <state>Sao Paulo</state>
        <zip>15090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Bernardo do Campo</city>
        <state>SP</state>
        <zip>09715</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20551</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01323</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04005</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04025</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 4B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 4K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Punta Arenas</city>
        <state>Magallanes Antartica</state>
        <zip>6212296</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Independencia</city>
        <state>Metropolitana</state>
        <zip>XXXXX</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>7600448</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vina Del Mar</city>
        <state>Valparaiso</state>
        <zip>2520000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shengyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>130016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Xian</city>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kladno</city>
        <zip>272 59</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Litomysl</city>
        <zip>570 14</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mestec Kralove</city>
        <zip>289 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ostrava Vitkovice</city>
        <zip>703 84</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ostrava</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 1</city>
        <zip>110 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 1</city>
        <zip>118 33</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Usti Nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Usti Nad Orlici</city>
        <zip>562 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herning</city>
        <zip>7400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hilleroed</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Horsens</city>
        <zip>8700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arras</city>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clermont-Ferrand Cedex 01</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Langres Cedex</city>
        <zip>52206</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Le Kremlin-Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Limoges Cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vernon</city>
        <zip>27200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Karlsbad</city>
        <zip>76307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mannheim</city>
        <zip>68163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Munchen</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pokfulman</city>
        <zip>XXXXX</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shatin, N.T</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Miskolc</city>
        <zip>3501</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500 082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bengaluru</city>
        <state>Karnataka</state>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mohali</city>
        <state>Punjab</state>
        <zip>160062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludhiana</city>
        <state>Tagore Nagar</state>
        <zip>141001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bangalore</city>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tiberias</city>
        <state>Lower Galillee</state>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hadera</city>
        <zip>38101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Castelfranco Veneto (Tv)</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chieti Scalo</city>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cosenza</city>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rozzano (Mi)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Daniele Del Friuli (Ud)</city>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vittorio Veneto (Tv)</city>
        <zip>31029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Busan</city>
        <zip>602-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>120752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>137-040</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>138736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Georgetown</city>
        <state>Penang</state>
        <zip>10350</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ipoh</city>
        <state>Perak</state>
        <zip>30990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melaka</city>
        <zip>75400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22500</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leon</city>
        <state>Guanajuato</state>
        <zip>37320</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44280</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64718</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Xalapa</city>
        <state>Veracruz</state>
        <zip>91020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durango</city>
        <zip>34080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Alesund</city>
        <zip>6017</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fredrikstad</city>
        <zip>1606</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gjettum</city>
        <zip>1346</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gjovik</city>
        <zip>2819</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamar</city>
        <zip>2318</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oslo</city>
        <zip>0456</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tynset</city>
        <zip>2500</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gdynia</city>
        <zip>81-348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Przeworsk</city>
        <zip>37-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warsawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warsaw</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>01-138</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coimbra</city>
        <zip>3004-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Guarda</city>
        <zip>6301-857</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lisboa</city>
        <zip>1169-050</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baia Mare</city>
        <zip>430031</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Targu Mures</city>
        <zip>540136</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kazan</city>
        <zip>420101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>109386</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115093</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>121359</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rostov-On Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192242</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bioemfontein</city>
        <state>Free State</state>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Parktown</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durban</city>
        <state>Kwa Zulu Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>Kwa Zulu Natal</state>
        <zip>3201</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bellville</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>George</city>
        <state>Western Cape</state>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torrevieja</city>
        <state>Alicante</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leon</city>
        <zip>24008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mourente</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chernihiv</city>
        <zip>14034</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kharkiv</city>
        <zip>61018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lviv</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Odesa</city>
        <zip>65117</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ternopil</city>
        <zip>46000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Livingston</city>
        <state>West Lothian</state>
        <zip>EH54 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
    <country>Turkey</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <results_first_submitted>March 4, 2014</results_first_submitted>
  <results_first_submitted_qc>March 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 10, 2014</results_first_posted>
  <last_update_submitted>April 17, 2014</last_update_submitted>
  <last_update_submitted_qc>April 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First participant, first visit: 27 August 2008; Last participant, last visit: 12 March 2013.</recruitment_details>
      <pre_assignment_details>5614 enrolled, 5395 randomized; Reasons for non-randomization: 173 did not meet inclusion/exclusion criteria; 12 withdrew consent; 5 had clinical reason to continue current treatment; 3 administrative reason by sponsor; 1 death; 1 adverse event (AE); 24 other reasons. 1 site (5 patients) excluded from analysis due to unconfirmed accuracy of data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Apixaban</title>
          <description>apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
Placebo for enoxaparin: solution, subcutaneous, 1milligram per kilogram (mg/kg) every 12 hours until sham international normalized ratio (INR) greater than, equal to ( ≥) 2.
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
        </group>
        <group group_id="P2">
          <title>Enoxaparin + Warfarin</title>
          <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2.
Warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized, Completed 6 Months of Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2691">15 participants were randomized to treatment but not treated.</participants>
                <participants group_id="P2" count="2704">15 participants were randomized to treatment but not treated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2314"/>
                <participants group_id="P2" count="2291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="413"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor or non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Fails to meet inclusion/exclusion</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Completed Study Follow Up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2617"/>
                <participants group_id="P2" count="2639"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2547">Of 70 who did not complete follow up: 7 completed treatment; 63 discontinued treatment</participants>
                <participants group_id="P2" count="2560">Of 79 who did not complete follow up: 3 completed treatment, 76 discontinued treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Apixaban</title>
          <description>apixaban: tablets, oral, 10 milligram (mg) tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months.
Placebo for enoxaparin: solution, subcutaneous, 1milligram per kilogram (mg/kg) every 12 hours until sham International normalized ratio (INR) greater than, equal to ( ≥) 2.
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
        </group>
        <group group_id="B2">
          <title>Enoxaparin + Warfarin</title>
          <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2.
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2691"/>
            <count group_id="B2" value="2704"/>
            <count group_id="B3" value="5395"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="15.98"/>
                    <measurement group_id="B2" value="56.7" spread="16.01"/>
                    <measurement group_id="B3" value="56.9" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than (&lt;) 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1729"/>
                    <measurement group_id="B2" value="1762"/>
                    <measurement group_id="B3" value="3491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt; 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="560"/>
                    <measurement group_id="B2" value="570"/>
                    <measurement group_id="B3" value="1130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than, equal to (&gt;=) 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1122"/>
                    <measurement group_id="B2" value="1106"/>
                    <measurement group_id="B3" value="2228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1569"/>
                    <measurement group_id="B2" value="1598"/>
                    <measurement group_id="B3" value="3167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Ethnicity was not collected outside of the United States.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2218"/>
                    <measurement group_id="B2" value="2243"/>
                    <measurement group_id="B3" value="4461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="380"/>
                    <measurement group_id="B3" value="747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2304"/>
                    <measurement group_id="B2" value="2306"/>
                    <measurement group_id="B3" value="4610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Portugal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="387"/>
                    <measurement group_id="B2" value="398"/>
                    <measurement group_id="B3" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="174"/>
                    <measurement group_id="B3" value="352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="205"/>
                    <measurement group_id="B3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Qualifying index Venous Thromboembolic Embolism</title>
          <description>Both the 2004 and 2008 American College of Chest Physicians (ACCP) recommendations for treatment of venous thromboembolic events (VTE) were used during this study and recommendations were consistent. Participants with provoked and unprovoked index events were summarized. For unprovoked events in participants with certain risk factors and medical conditions, such as cancer, an idiopathic event, presence of pro-thrombotic genotype, or presence of a marker indicative of an increased risk of recurrent thromboembolism treatment for 6 months or longer is supported by the ACCP guidelines.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Provoked Index VTE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272"/>
                    <measurement group_id="B2" value="272"/>
                    <measurement group_id="B3" value="544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unprovoked Index VTE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2416"/>
                    <measurement group_id="B2" value="2429"/>
                    <measurement group_id="B3" value="4845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Index Event Classification</title>
          <description>Participants with events of either deep vein thrombosis (DVT) or pulmonary embolism (PE) were enrolled. If a participant had both DVT and PE, the participant was classified to PE. Each participant was counted once in a category but could be counted in more than one category. An Independent Central Adjudication Committee (ICAC) reviewed participants in a blinded manner. The ICAC included a chairman and independent reviewers who were physicians with experience in vascular medicine and thrombosis. The ICAC adjudicated all index events (proximal DVT and/or PE).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Proximal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1778"/>
                    <measurement group_id="B2" value="1814"/>
                    <measurement group_id="B3" value="3592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="913"/>
                    <measurement group_id="B2" value="890"/>
                    <measurement group_id="B3" value="1803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjudicated Proximal DVT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1749"/>
                    <measurement group_id="B2" value="1783"/>
                    <measurement group_id="B3" value="3532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adjudicated PE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="930"/>
                    <measurement group_id="B2" value="906"/>
                    <measurement group_id="B3" value="1836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment</title>
        <description>VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)</time_frame>
        <population>All randomized participants with a non-missing primary endpoint (n/N: 59/2609; 71/2635, in apixaban, enoxaparin/warfarin, respectively). Intent-to-treat population. Confidence interval (CI) for event rate calculated based on the Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment</title>
          <description>VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat).</description>
          <population>All randomized participants with a non-missing primary endpoint (n/N: 59/2609; 71/2635, in apixaban, enoxaparin/warfarin, respectively). Intent-to-treat population. Confidence interval (CI) for event rate calculated based on the Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2609"/>
                <count group_id="O2" value="2635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0226" lower_limit="0.0169" upper_limit="0.0283"/>
                    <measurement group_id="O2" value="0.0269" lower_limit="0.0208" upper_limit="0.0331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis that apixaban was non-inferior to enoxaparin/warfarin therapy in preventing the recurrence of VTE (nonfatal DVT or nonfatal PE)/VTE-related death.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Statistical Testing: non-inferiority tested at 1-sided α=0.025 with margin of 1.8. Demonstration of non-inferiority using both relative risk (RR) (margin = 1.8) and risk difference (RD) (margin = 0.035) were required to achieve the primary objective.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This is the first test in a sequential testing sequence. p-value calculated based on the Yanagawa-Tango-Hiejima test stratified by index event strata for non-inferiority. Tested at 1-sided α=0.025</p_value_desc>
            <method>Yanagawa-Tango-Hiejima</method>
            <method_desc>For a successful trial; rejection of the null hypotheses for both RR and RD was required.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.8390</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5965</ci_lower_limit>
            <ci_upper_limit>1.1802</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis that apixaban was non-inferior to enoxaparin/warfarin therapy in preventing the recurrence of VTE (nonfatal DVT or nonfatalPE)/VTE-related death as measured by risk difference.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Statistical Testing; non-inferiority tested at 1-sided α=0.025. If non-inferiority demonstrated for both RR and RD, the primary objective was achieved.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Yanagawa-Tango-Hiejima test statistic for risk difference (RD).</p_value_desc>
            <method>Yanagawa-Tango-Hiejima</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.0044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0128</ci_lower_limit>
            <ci_upper_limit>0.0040</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint. Inferential testing required demonstration of non-inferiority using both RR and RD plus demonstration of superiority for major bleeding.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3128</p_value>
            <p_value_desc>Tested at 2-sided α=0.05 significance. Further inferential statistical testing halted due to failure to reject the null hypothesis of equivalence for VTE/VTE-related death.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Relative risk, CI, and p-value were calculated based on CMH test stratified by index event strata.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.8390</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5965</ci_lower_limit>
            <ci_upper_limit>1.1802</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death</title>
        <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.</description>
        <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>All randomized participants with non-missing secondary endpoint (n/N: 84/2609; 104/2635, in apixaban, enoxaparin/warfarin arms, respectively). Participants categorized to assigned arm, regardless of treatment actually received. Intent to Treat principle. Confidence interval (CI) for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Composite of Recurrent Symptomatic Venous Thromboembolism (VTE) or All-Cause Death</title>
          <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded.</description>
          <population>All randomized participants with non-missing secondary endpoint (n/N: 84/2609; 104/2635, in apixaban, enoxaparin/warfarin arms, respectively). Participants categorized to assigned arm, regardless of treatment actually received. Intent to Treat principle. Confidence interval (CI) for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2609"/>
                <count group_id="O2" value="2635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0322" lower_limit="0.0254" upper_limit="0.0390"/>
                    <measurement group_id="O2" value="0.0395" lower_limit="0.0320" upper_limit="0.0469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1554</p_value>
            <p_value_desc>The test was stratified by index event strata using alpha=0.05 level of significance. Analysis was performed on the secondary efficacy dataset; there was no imputation of missing data.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Nominal p-value is reported.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.8151</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6146</ci_lower_limit>
            <ci_upper_limit>1.0812</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death</title>
        <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.</description>
        <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>All randomized participants with non-missing secondary endpoint (n/N: 61/2609; 77/2635, in apixaban, enoxaparin/warfarin arms, respectively). Participants categorized to assigned arm, regardless of treatment actually received. Intent to Treat principle. CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or Cardiovascular (CV)-Related Death</title>
          <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite.</description>
          <population>All randomized participants with non-missing secondary endpoint (n/N: 61/2609; 77/2635, in apixaban, enoxaparin/warfarin arms, respectively). Participants categorized to assigned arm, regardless of treatment actually received. Intent to Treat principle. CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2609"/>
                <count group_id="O2" value="2635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0234" lower_limit="0.0176" upper_limit="0.0292"/>
                    <measurement group_id="O2" value="0.0292" lower_limit="0.0228" upper_limit="0.0357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1848</p_value>
            <p_value_desc>The test was stratified by index event strata using alpha=0.05 level of significance. . Nominal p-value is reported.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Analysis was performed on the secondary efficacy dataset; there was no imputation of missing data.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.7994</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5737</ci_lower_limit>
            <ci_upper_limit>1.1137</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding</title>
        <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle</description>
        <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants in each randomized arm, excluded those with missing endpoint and included those not in the efficacy evaluable population with bleeding event which occurred during treatment (n/N: 73/2610; 118/2635). Confidence interval (CI) for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE or VTE-related Death or Major Bleeding</title>
          <description>VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle</description>
          <population>Total number of participants in each randomized arm, excluded those with missing endpoint and included those not in the efficacy evaluable population with bleeding event which occurred during treatment (n/N: 73/2610; 118/2635). Confidence interval (CI) for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2610"/>
                <count group_id="O2" value="2635"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0280" lower_limit="0.0216" upper_limit="0.0343"/>
                    <measurement group_id="O2" value="0.0448" lower_limit="0.0369" upper_limit="0.0527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>The test was stratified by index event strata using alpha=0.05 level of significance. Nominal p-value is reported.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.6236</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4682</ci_lower_limit>
            <ci_upper_limit>0.8306</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding</title>
        <description>VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).</description>
        <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number participants in each treatment group, excluded those with missing endpoint and included those not in the efficacy evaluable population with bleeding event which occurred during treatment (n/N: 183/2617; 333/2641). Events included as per ITT principle. CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2 Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Composite of Recurrent Symptomatic VTE, Myocardial Infarction, Stroke, CV-related Death, Clinically Relevant Non-major (CRNM) Bleeding or Major Bleeding</title>
          <description>VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT).</description>
          <population>Total number participants in each treatment group, excluded those with missing endpoint and included those not in the efficacy evaluable population with bleeding event which occurred during treatment (n/N: 183/2617; 333/2641). Events included as per ITT principle. CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2617"/>
                <count group_id="O2" value="2641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0699" lower_limit="0.0602" upper_limit="0.0797"/>
                    <measurement group_id="O2" value="0.1261" lower_limit="0.1134" upper_limit="0.1387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The test was stratified by index event strata using alpha=0.05 level of significance. Nominal p-value is reported.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.5532</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4658</ci_lower_limit>
            <ci_upper_limit>0.6569</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period</title>
        <description>DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).</description>
        <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants in each randomized arm (ITT), excluding those with missing endpoint (n/N: 22/2608; 35/2633). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Symptomatic Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period</title>
          <description>DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).</description>
          <population>Total number of participants in each randomized arm (ITT), excluding those with missing endpoint (n/N: 22/2608; 35/2633). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2608"/>
                <count group_id="O2" value="2633"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0084" lower_limit="0.0049" upper_limit="0.0119"/>
                    <measurement group_id="O2" value="0.0133" lower_limit="0.0089" upper_limit="0.0177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.6347</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3735</ci_lower_limit>
            <ci_upper_limit>1.0787</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period</title>
        <description>PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).</description>
        <time_frame>Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants in each randomized arm (ITT), excluding those with missing endpoint (n/N: 27/2606; 25/2632). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Symptomatic Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period</title>
          <description>PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early).</description>
          <population>Total number of participants in each randomized arm (ITT), excluding those with missing endpoint (n/N: 27/2606; 25/2632). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2606"/>
                <count group_id="O2" value="2632"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0104" lower_limit="0.0065" upper_limit="0.0142"/>
                    <measurement group_id="O2" value="0.0095" lower_limit="0.0058" upper_limit="0.0132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.0935</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6363</ci_lower_limit>
            <ci_upper_limit>1.8793</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period</title>
        <description>VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants in respective treatment groups excluding participants with missing endpoint information. (n/N: 12/2608; 16/2630). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Venous Thromboembolism (VTE)-Related Death During the Intended Treatment Period</title>
          <description>VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).</description>
          <population>Total number of participants in respective treatment groups excluding participants with missing endpoint information. (n/N: 12/2608; 16/2630). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2608"/>
                <count group_id="O2" value="2630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0046" lower_limit="0.0020" upper_limit="0.0072"/>
                    <measurement group_id="O2" value="0.0061" lower_limit="0.0031" upper_limit="0.0091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.7521</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3560</ci_lower_limit>
            <ci_upper_limit>1.5889</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period</title>
        <description>VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants in respective groups excluding those with missing endpoint information (n/N: 15/2608; 23/2630). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Cardiovascular (CV)-Related Death Including VTE-related Death During the Intended Treatment Period</title>
          <description>VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle).</description>
          <population>Total number of participants in respective groups excluding those with missing endpoint information (n/N: 15/2608; 23/2630). CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2608"/>
                <count group_id="O2" value="2630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0058" lower_limit="0.0028" upper_limit="0.0087"/>
                    <measurement group_id="O2" value="0.0087" lower_limit="0.0052" upper_limit="0.0123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.6539</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3419</ci_lower_limit>
            <ci_upper_limit>1.2508</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All-Cause Death During the Intended Treatment Period</title>
        <description>Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants excluding those with missing endpoint (n/N: 41/2608; 52/2630). Events included regardless of whether or not participant received treatment, ie, ITT principle. CI for event rate calculated based on Wald asymptotic confidence limits.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All-Cause Death During the Intended Treatment Period</title>
          <description>Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information).</description>
          <population>Total number of participants excluding those with missing endpoint (n/N: 41/2608; 52/2630). Events included regardless of whether or not participant received treatment, ie, ITT principle. CI for event rate calculated based on Wald asymptotic confidence limits.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2608"/>
                <count group_id="O2" value="2630"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0157" lower_limit="0.0109" upper_limit="0.0205"/>
                    <measurement group_id="O2" value="0.0198" lower_limit="0.0145" upper_limit="0.0251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.7934</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5287</ci_lower_limit>
            <ci_upper_limit>1.1906</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants</title>
        <description>All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants receiving at least one dose of study drug n/N: 15/2676; 49/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Major Bleeding During the Treatment Period in Treated Participants</title>
          <description>All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
          <population>Total number of participants receiving at least one dose of study drug n/N: 15/2676; 49/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2676"/>
                <count group_id="O2" value="2689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0056" lower_limit="0.0028" upper_limit="0.0084"/>
                    <measurement group_id="O2" value="0.0182" lower_limit="0.0132" upper_limit="0.0233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hypothesis: apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint. As per the hierarchical statistical testing cascade, inferential testing for adjudicated major bleeding occurred because non-inferiority for VTE/VTE-related death (Primary efficacy endpoint) was demonstrated earlier. Rejection of the null hypothesis for equivalence for major bleeding allowed inferential testing for superiority of VTE/VTE-related death.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value calculated on the CMH test stratified by index event strata.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.3070</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1728</ci_lower_limit>
            <ci_upper_limit>0.5452</ci_upper_limit>
            <estimate_desc>Relative risk and CI were calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants</title>
        <description>Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants receiving at least one dose of study drug n/N: 115/2676; 261/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Major/CRNM Bleeding During the Treatment Period in Treated Participants</title>
          <description>Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug).</description>
          <population>Total number of participants receiving at least one dose of study drug n/N: 115/2676; 261/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2676"/>
                <count group_id="O2" value="2689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0430" lower_limit="0.0353" upper_limit="0.0507"/>
                    <measurement group_id="O2" value="0.0971" lower_limit="0.0859" upper_limit="0.1083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint. Inferential testing was not conducted because the null hypothesis pertaining to superiority for VTE/VTE-related death was not rejected.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Tested at 2-sided alpha=0.05 significance.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Nominal p-value is reported.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.4410</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3566</ci_lower_limit>
            <ci_upper_limit>0.5453</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants</title>
        <description>Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants receiving at least one dose of study drug n/N: 103/2676; 215/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Clinically Relevant Non Major (CRNM) Bleeding During the Treatment Period in Treated Participants</title>
          <description>Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis &gt;5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
          <population>Total number of participants receiving at least one dose of study drug n/N: 103/2676; 215/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2676"/>
                <count group_id="O2" value="2689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0385" lower_limit="0.0312" upper_limit="0.0458"/>
                    <measurement group_id="O2" value="0.0800" lower_limit="0.0697" upper_limit="0.0902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Tested at 2-sided alpha=0.05 significance.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Nominal p-value is reported.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.4793</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3815</ci_lower_limit>
            <ci_upper_limit>0.6022</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants</title>
        <description>Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants receiving at least one dose of study drug n/N: 313/2676; 505/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Minor Bleeding During the Treatment Period in Treated Participants</title>
          <description>Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
          <population>Total number of participants receiving at least one dose of study drug n/N: 313/2676; 505/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2676"/>
                <count group_id="O2" value="2689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1170" lower_limit="0.1048" upper_limit="0.1291"/>
                    <measurement group_id="O2" value="0.1878" lower_limit="0.1730" upper_limit="0.2026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Tested at 2-sided alpha=0.05 significance.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Nominal p-value is reported.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.6182</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5432</ci_lower_limit>
            <ci_upper_limit>0.7034</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants</title>
        <description>Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>Total number of participants receiving at least one dose of study drug n/N: 402/2676; 676/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adjudicated Total Bleeding During the Treatment Period in Treated Participants</title>
          <description>Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received.</description>
          <population>Total number of participants receiving at least one dose of study drug n/N: 402/2676; 676/2689, in apixaban and enoxaparin/warfarin groups, respectively. CI for event rate calculated based on Wald asymptotic confidence limits. Participants were categorized according to the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2676"/>
                <count group_id="O2" value="2689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1502" lower_limit="0.1367" upper_limit="0.1638"/>
                    <measurement group_id="O2" value="0.2514" lower_limit="0.2350" upper_limit="0.2678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exploratory hypothesis of apixaban therapy being superior to enoxaparin/warfarin therapy for the adjudicated endpoint.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Tested at 2-sided alpha=0.05 significance.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Nominal p-value is reported.</method_desc>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.5937</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5318</ci_lower_limit>
            <ci_upper_limit>0.6629</ci_upper_limit>
            <estimate_desc>Relative Risk and CI was calculated based on CMH test stratified by index event strata.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants</title>
        <description>Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
        <time_frame>First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued</time_frame>
        <population>Total number of participants receiving at least one dose of study drug. Participants were categorized according to the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Bleeding AEs, Discontinuations Due to AEs and Death During the Treatment Period in Treated Participants</title>
          <description>Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
          <population>Total number of participants receiving at least one dose of study drug. Participants were categorized according to the actual treatment received.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2676"/>
                <count group_id="O2" value="2689"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1795"/>
                    <measurement group_id="O2" value="1923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="417"/>
                    <measurement group_id="O2" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding AE or SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="415"/>
                    <measurement group_id="O2" value="695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinued Due to AE or SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests</title>
        <description>Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: &lt; 0.75*LLN, &gt; 1.25*ULN; Hemoglobin: &lt;= 11.5 g/dL (males), &lt;= 9.5 g/dL (females); Hematocrit: &lt;= 37% (males), &lt;= 32% (females); Erythrocytes: &lt;0.75*10^6 c/µL*PreRx; Platelet count: &lt; 75*10^9 c/L, &gt; 700*10^9 c/L; ANC: &lt; 1.00*10^3 c/µL; Abs eosinophils: &gt; 0.750*10^3 c/µL; Abs Basophils: &gt; 400/MM^3; Abs Monocytes&gt; 2000/MM^3; Abs Lymphocytes: &lt; 0.750*10*3 c/ µL, &gt; 7.5*10^3 c/ µL.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treated Participants With Marked Abnormalities in Hematology Laboratory Tests</title>
          <description>Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: &lt; 0.75*LLN, &gt; 1.25*ULN; Hemoglobin: &lt;= 11.5 g/dL (males), &lt;= 9.5 g/dL (females); Hematocrit: &lt;= 37% (males), &lt;= 32% (females); Erythrocytes: &lt;0.75*10^6 c/µL*PreRx; Platelet count: &lt; 75*10^9 c/L, &gt; 700*10^9 c/L; ANC: &lt; 1.00*10^3 c/µL; Abs eosinophils: &gt; 0.750*10^3 c/µL; Abs Basophils: &gt; 400/MM^3; Abs Monocytes&gt; 2000/MM^3; Abs Lymphocytes: &lt; 0.750*10*3 c/ µL, &gt; 7.5*10^3 c/ µL.</description>
          <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2599"/>
                <count group_id="O2" value="2593"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erthrocytes Low (N=2599, 2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit Low (N=2588, 2587)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin Low (N=2599, 2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count Low (N=2594, 2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes Low (N=2528, 2519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes High (N=2528, 2519)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Basophils High (N=2594,2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Eosinophils High (N=2594,2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Lyphocytes Low (N=2594,2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Lyphocytes High (N=2594,2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Monocytes High (N=2594,2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absolute Neutrophils Low (N=2594,2589)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests</title>
        <description>Bicarbonate milliequivalents/Liter (mEq/L) Low/High: &lt; 0.75*LLN or &gt; 1.25*ULN, or if pre-dose &lt; LLN then use &lt; 0.75*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.25*pre-dose or &lt; LLN; Serum Calcium mg/dL Low/High: &lt; 0.8*LLN or &gt; 1.2*ULN, or if pre-dose &lt; LLN then use &lt; 0.75*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.25*pre-dose or &lt; LLN; Serum Chloride mEq/L: &lt; 0.9*LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use &lt; 0.9*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.1*pre-dose or &lt; LLN; Serum Potassium mEq/L: &lt; 0.9*LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use &lt; 0.9*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.1*pre-dose or &lt; LLN; Serum Sodium mEq/L: &lt; 0.95*LLN or &gt; 1.05*ULN, or if pre-dose &lt; LLN then use &lt; 0.95*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.05*pre-dose or &lt; LLN.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treated Participants With Marked Abnormalities in Electrolyte Laboratory Tests</title>
          <description>Bicarbonate milliequivalents/Liter (mEq/L) Low/High: &lt; 0.75*LLN or &gt; 1.25*ULN, or if pre-dose &lt; LLN then use &lt; 0.75*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.25*pre-dose or &lt; LLN; Serum Calcium mg/dL Low/High: &lt; 0.8*LLN or &gt; 1.2*ULN, or if pre-dose &lt; LLN then use &lt; 0.75*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.25*pre-dose or &lt; LLN; Serum Chloride mEq/L: &lt; 0.9*LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use &lt; 0.9*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.1*pre-dose or &lt; LLN; Serum Potassium mEq/L: &lt; 0.9*LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use &lt; 0.9*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.1*pre-dose or &lt; LLN; Serum Sodium mEq/L: &lt; 0.95*LLN or &gt; 1.05*ULN, or if pre-dose &lt; LLN then use &lt; 0.95*pre-dose or &gt; ULN if pre-dose &gt; ULN then use &gt; 1.05*pre-dose or &lt; LLN.</description>
          <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2601"/>
                <count group_id="O2" value="2596"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bicarbonate Low (N=2600,2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate High (N=2600,2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium Low (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Calcium High (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Low Total Calcium Low (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride Low Total Calcium High (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium Low (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium High (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Low (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium Low (N=2601,2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests</title>
        <description>Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: &gt; 1.5*ULN; Creatinine mg/dL: &gt; 1.5*ULN; Alanine aminotransferase (ALT) U/L: &gt; 3*ULN; Aspartate aminotransferase (AST) U/L: &gt; 3*ULN; Alkaline phosphatase U/L: &gt; 2*ULN; Bilirubin Direct mg/dL: &gt; 1.5*ULN; Bilirubin Total mg/dL: &gt; 2*ULN.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treated Participants With Marked Abnormalities in Kidney and Liver Function Laboratory Tests</title>
          <description>Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: &gt; 1.5*ULN; Creatinine mg/dL: &gt; 1.5*ULN; Alanine aminotransferase (ALT) U/L: &gt; 3*ULN; Aspartate aminotransferase (AST) U/L: &gt; 3*ULN; Alkaline phosphatase U/L: &gt; 2*ULN; Bilirubin Direct mg/dL: &gt; 1.5*ULN; Bilirubin Total mg/dL: &gt; 2*ULN.</description>
          <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2601"/>
                <count group_id="O2" value="2598"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BUN High (N=517, 523)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine High (N=2601, 2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT High (N=2601, 2598)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP High (N=2601, 2598)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST High (N=2601, 2598)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin High (N=2601, 2593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin High (N=2601, 2597)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests</title>
        <description>Creatine kinase High: &gt;5*ULN Units/Liter (U/L); Total Protein High/Low: &lt; 0.9 *LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use 0.9* pre-dose or &gt; ULN if pre-dose &gt; ULN then use 1.1 *pre-dose or &lt;LLN; Uric acid High: &gt; 1.5* ULN, or if pre-dose &gt; ULN then use &gt; 2 *pre-dose.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treated Participants With Marked Abnormalities in Creatine Kinase, Uric Acid, and Total Protein Laboratory Tests</title>
          <description>Creatine kinase High: &gt;5*ULN Units/Liter (U/L); Total Protein High/Low: &lt; 0.9 *LLN or &gt; 1.1*ULN, or if pre-dose &lt; LLN then use 0.9* pre-dose or &gt; ULN if pre-dose &gt; ULN then use 1.1 *pre-dose or &lt;LLN; Uric acid High: &gt; 1.5* ULN, or if pre-dose &gt; ULN then use &gt; 2 *pre-dose.</description>
          <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2601"/>
                <count group_id="O2" value="2596"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatine Kinase High (N=2601, 2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric Acid High (N=2601, 2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein Low (N=2601, 2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein High (N=2601, 2596)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests</title>
        <description>All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.</description>
        <time_frame>Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)</time_frame>
        <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
          </group>
          <group group_id="O2">
            <title>Enoxaparin + Warfarin</title>
            <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treated Participants With Marked Abnormalities in Urinalysis Laboratory Tests</title>
          <description>All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4.</description>
          <population>N=Treated participants who received at least one dose of study drug and had non-missing laboratory measurements.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1685"/>
                <count group_id="O2" value="1719"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood in Urine High (N=2289, 2273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose in Urine High (N=2289, 2273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocyte Esterase in Urine High (N=2289, 2273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein in Urine High (N=2289, 2273)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC + WBC in Urine High (N=1685, 1719)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC in Urine High (N=1293, 1389)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC in Urine High (N=1354, 1361)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274"/>
                    <measurement group_id="O2" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 up to 24 Weeks + 2 Days or 355 Days (for those participants who discontinued early)/</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apixaban</title>
          <description>Apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
Placebo for enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2
Placebo for warfarin: tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months</description>
        </group>
        <group group_id="E2">
          <title>Enoxaparin/Warfarin</title>
          <description>Enoxaparin: solution, subcutaneous, 1 mg/kg Q12h until INR ≥2
warfarin: tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
Placebo for apixaban: tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="417" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="410" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ANAEMIA MEGALOBLASTIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HILAR LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DILATATION VENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERICARDIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PRINZMETAL ANGINA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENTRICULAR HYPOKINESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>SICKLE CELL ANAEMIA WITH CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>INNER EAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COLONIC POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DIAPHRAGMATIC HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DUODENOGASTRIC REFLUX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRIC POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HYPOMOTILITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATITIS RELAPSING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERITONEAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TONGUE OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>AXILLARY PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DEVICE OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PELVIC MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DRUG-INDUCED LIVER INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEPATIC CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEPATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGY TO ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BEHCET'S SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRONCHITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE VEGETATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CELLULITIS ORBITAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GROIN ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HELICOBACTER GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INFECTED SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MASTOIDITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MYCOBACTERIAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERINEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECI PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PURULENT PERICARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TULARAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VULVAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ACCIDENTAL OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DRUG ADMINISTRATION ERROR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>EXTRADURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INCORRECT DOSE ADMINISTERED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LOWER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL REOCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COAGULATION TIME PROLONGED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FRACTURE MALUNION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LIGAMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LIMB DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PATHOLOGICAL FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>POLYMYALGIA RHEUMATICA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PSEUDARTHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BENIGN OVARIAN TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BILE DUCT CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BLADDER PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BLADDER TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BONE NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRAIN CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BREAST CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRONCHIAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CERVIX NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CHOLESTEATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COLON CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ENDOCRINE NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ESSENTIAL THROMBOCYTHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GALLBLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTRIC CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL STROMAL TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL TRACT ADENOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GLIOBLASTOMA MULTIFORME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEPATIC CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG SQUAMOUS CELL CARCINOMA STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MALIGNANT PERITONEAL NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASES TO ABDOMINAL CAVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASES TO BONE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASES TO PERITONEUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTATIC CARCINOMA OF THE BLADDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METASTATIC RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ONCOCYTOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANCREATIC NEUROENDOCRINE TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PARAPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PELVIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>POLYCYTHAEMIA VERA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER RECURRENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RECTOSIGMOID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TESTIS CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THYROID CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THYROID NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TRANSITIONAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TUMOUR ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UTERINE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>COMPLEX REGIONAL PAIN SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEURITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PARAPLEGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERONEAL NERVE PALSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THALAMIC INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PREGNANCY</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ADJUSTMENT DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ALCOHOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>APATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BIPOLAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DEPRESSION SUICIDAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GLOMERULONEPHRITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GLOMERULONEPHRITIS MEMBRANOPROLIFERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE URINARY TRACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL CYST HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>URINARY BLADDER HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>URINARY TRACT OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOMETRIAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ADENOIDAL HYPERTROPHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ALLERGIC GRANULOMATOUS ANGIITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ASTHMATIC CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BRONCHOSTENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>LUNG CONSOLIDATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY ALVEOLAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY AMYLOIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY ARTERIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>CAPILLARITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>CUTANEOUS VASCULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE SUBCUTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PURPURA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SKIN NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY OF PARTNER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>AORTIC RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ARTERIAL THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>EMBOLISM VENOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>TEMPORAL ARTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENOUS STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1014" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="1207" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERCHOLESTEROLAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="2689"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="2676"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="2689"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

